Exploring the effects of metatine e-cigarettes on young adults
Perceptions of Vaping Products Among Young Adults
NA · Ohio State University Comprehensive Cancer Center · NCT06868368
This study is testing how metatine e-cigarettes affect young adults by looking at how they feel about them and how the body processes this new type of nicotine compared to regular e-cigarettes.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 21 Years to 34 Years |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center (other) |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT06868368 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the pharmacokinetics, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults aged 21-34. Participants will be randomized to use one of three types of e-cigarettes during three sessions, where they will vape ad-libitum for 30 minutes and complete surveys regarding their perceptions. The study also includes blood draws to assess the pharmacokinetics of metatine compared to traditional nicotine e-cigarettes.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 21-34 who are current users of nicotine e-cigarettes.
Not a fit: Patients who are not current e-cigarette users or those with significant health issues related to lung or cardiac conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the safety and appeal of metatine e-cigarettes, potentially guiding public health policies and smoking cessation strategies.
How similar studies have performed: While there have been studies on nicotine e-cigarettes, the specific focus on metatine is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 21-34 years * Current nicotine EC user (defined as ≥ weekly use over the past 3 months) * Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions * Read and speak English Exclusion Criteria: * Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months) * Unstable or significant psychiatric conditions (past and stable conditions will be allowed) * History of cardiac event or distress within the past 3 months * Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days * Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test) * Have hemophilia or another type of bleeding disorder * Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability
Where this trial is running
Columbus, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (RECRUITING)
Study contacts
- Principal investigator: Alayna P Tackett, PhD — Ohio State University Comprehensive Cancer Center
- Study coordinator: The Ohio State University Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 800-293-5066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Abuse Tobacco, Exposure